Close Menu

NEW YORK (GenomeWeb) – Molecular diagnostics firm Bioarray Genetics on Thursday said that it has received $4 million in Series B equity financing.

The funding came from Quark Venture and GF Securities through their Global Health Science Fund and Connecticut Innovations, and will be used to move Bioarray Genetics' first product, BA100, a breast cancer diagnostic, to clinicians. The financing will also be used for R&D for other tests, including those targeting treatments for metastatic breast and colon cancers, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.